
Opinion|Videos|March 4, 2025
Third-Line Treatments and Current Practice Guidelines in Advanced RCC
Author(s)Pedro Barata, MD, MSc, FACP
A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
Episodes in this series

Video content above is prompted by the following:
- What are the third-line options for this patient per the NCCN guidelines for kidney cancer?





































